On November 15, 2021 IKENA Oncology (IKENA; Boston, MA, USA) reported that an investigator-initiated trial of IK-007 (AskAt’s EP4 antagonist AAT-007) in metastatic inflammatory breast cancer was launched in September 2021, led by Naoto Ueno, M.D., of the University of Texas MD Anderson Cancer Center(Press release, AskAt, NOV 15, 2021, View Source [SID1234595538]). The company made this announcement in its Third Quarter 2021 financial results and corporate update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!